| Product NDC: | 65862-072 |
| Proprietary Name: | Stavudine |
| Non Proprietary Name: | Stavudine |
| Active Ingredient(s): | 1 mg/mL & nbsp; Stavudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | POWDER, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 65862-072 |
| Labeler Name: | Aurobindo Pharma Limited |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA077774 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20081229 |
| Package NDC: | 65862-072-02 |
| Package Description: | 1 BOTTLE in 1 CARTON (65862-072-02) > 200 mL in 1 BOTTLE |
| NDC Code | 65862-072-02 |
| Proprietary Name | Stavudine |
| Package Description | 1 BOTTLE in 1 CARTON (65862-072-02) > 200 mL in 1 BOTTLE |
| Product NDC | 65862-072 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Stavudine |
| Dosage Form Name | POWDER, FOR SOLUTION |
| Route Name | ORAL |
| Start Marketing Date | 20081229 |
| Marketing Category Name | ANDA |
| Labeler Name | Aurobindo Pharma Limited |
| Substance Name | STAVUDINE |
| Strength Number | 1 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |